Why Is Cancer Focused CEL-SCI Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
CEL-SCI Corporation (AMEX:CVM) stock is trading higher after the announcement that the British National Institute for Health and Care Excellence (NICE) has selected its drug Multikine to be evaluated as a potential new standard of care for squamous cell carcinoma of the head and neck (SCCHN) in the U.K. The selection is based on phase III clinical trial results indicating a significant 5-year survival benefit. CEL-SCI's CEO Geert Kersten expressed encouragement over this development. CVM shares have surged 41% to $2.92.
December 04, 2023 | 4:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CEL-SCI Corporation's stock has risen sharply following the news that its drug Multikine is being evaluated by NICE as a potential standard of care for SCCHN in the U.K.
The positive response from NICE regarding Multikine is a significant endorsement of CEL-SCI's product, which could lead to increased adoption and sales if it becomes a standard of care. This news is likely to boost investor confidence and drive short-term stock price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100